RxDoctor Payments Data

Leonid Shegelman

Psychiatry · Brooklyn, NYNPI 1639182066

Payments from drug & device makers

$4,564in general payments, 2019–2025

Across 112 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$963
  • Lundbeck LLC$625
  • E.r. Squibb & Sons, L.L.C.$599
  • AbbVie$281
  • Johnson & Johnson$280
  • plus $722 from 9 others

What the payments were for

  • Food & beverage$4,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,564 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$152,573
Medicare patients
211
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate56$89,092
LatudaLurasidone Hcl45$60,296
Abilify MaintenaAripiprazole25$55,960
RexultiBrexpiprazole35$55,337
NamzaricMemantine Hcl/Donepezil Hcl89$49,272
TrintellixVortioxetine Hydrobromide93$46,527
VraylarCariprazine Hcl30$41,392
BelsomraSuvorexant63$26,731
Risperdal ConstaRisperidone Microspheres24$18,989
Aripiprazole250$10,767
Risperidone ErRisperidone Microspheres13$8,196
SeroquelQuetiapine Fumarate26$7,562
Lurasidone Hcl23$6,245
Doxepin Hcl66$5,183
KlonopinClonazepam27$5,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,094$111,29760 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$280$108,08180 claims
AbbVieNamzaric, Vraylar$281$90,664119 claims
Sunovion Pharmaceuticals Inc.Latuda$122$60,29645 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$130$46,52793 claims
Almatica Pharma LLCSertraline Hcl$37$843341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →